HBV AND 1018 ISS VACCINE FORMULATION IN NEWBORN BABOONS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a two-part study. The objective of this experiment is to test for the first time in newborn baboons the immunogenicity of a hepatitis B virus (HBV) vaccine formulation, consisting of immunostimulatory DNA sequences (1018 ISS) mixed with yeast-recombinant hepatitis B surface antigen (HBsAg). This experiment will help determine if this vaccine can elicit antibodies in newborn baboons, and help identify the optimal dose for 1018 ISS, and the optimal vaccination schedule. This study will evaluate the ability of this vaccine to induce an antibody response in baboons to HBsAg equivalent to a commercial vaccine formulation that is used to immunize human infants. Historically, adult baboons have shown to be a good model for HBV vaccines, such as those containing HBsAg plus 1018 ISS. These studies will help decide if the HBV and ISS vaccine formulation can elicit responses in newborn baboons equivalent to the commercial HBV vaccine, which will assist in the development of a new HBV vaccine for human infants.